SVRA (Savara) Total Liabilities: $45.61 Mil (As of Mar. 2026)


SVRA Savara Inc SVRA
19 GF Score
Price $6.22
! 3 Warning Signs
View Full Analysis

What is Savara Total Liabilities?

Savara SVRA +2.47% 19 Total Liabilities is $45.61 Mil as of Mar. 2026. GuruFocus rates SVRA with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

Savara's Total Liabilities for the quarter that ended in Mar. 2026 was $45.61 Mil.

Savara's quarterly Total Liabilities increased from Sep. 2025 ($46.54 Mil) to Dec. 2025 ($50.30 Mil) but then declined from Dec. 2025 ($50.30 Mil) to Mar. 2026 ($45.61 Mil).

Savara's annual Total Liabilities increased from Dec. 2023 ($37.19 Mil) to Dec. 2024 ($41.43 Mil) and increased from Dec. 2024 ($41.43 Mil) to Dec. 2025 ($50.30 Mil).

Savara Total Liabilities Historical Data

* Premium members only.

The historical data trend for Savara's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Savara Total Liabilities Chart

Savara Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.10 32.00 37.19 41.43 50.30

Savara Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.47 43.28 46.54 50.30 45.61
SVRA
19GF Score
Savara Inc SVRA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Savara Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Savara's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=20.396+(29.907+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=50.30

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=253.436-203.133
=50.30

Savara's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.539+(30.067+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=45.61

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=221.645-176.039
=45.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $45.61 Mil mean?
Savara (SVRA) has a Total Liabilities of $45.61 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Savara and its competitors.
Is Savara's Total Liabilities too high?
Savara's current Total Liabilities is $45.61 Mil. Overall, Savara has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Savara's Total Liabilities compare to SPTX and EYPT?
Savara's Total Liabilities of $45.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Savara and its competitors. Savara's current Total Liabilities is $45.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Savara stock overvalued right now?
Savara (SVRA) has a current Total Liabilities of $45.61 Mil. The current Total Liabilities is $45.61 Mil. Savara's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Savara (SVRA), the current Total Liabilities is $45.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Savara Business Description

Other Exchanges YB4P:Germany
Address 1717 Langhorne Newtown Road, Suite 300, One Summit Square, Langhorne, PA, USA, 19047
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
19GF Score

Get the complete analysis for SVRA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.22
Price